Koers Rezolute, Inc. Other OTC
Aandelen
US76200L1017
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 23,49 mln. 21,68 mln. | Marktkapitalisatie | 166 mln. 153 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -63 mln. -58,15 mln. | Nettowinst (verlies) 2025 * | -49 mln. -45,23 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 86 mln. 79,38 mln. | Nettoliquiditeiten 2025 * | 68 mln. 62,77 mln. | EV/omzet 2025 * | 4,16 x |
K/w-verhouding 2024 * |
-3,52
x | K/w-verhouding 2025 * |
-5,27
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 79,62% |
Recentste transcriptie over Rezolute, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 66 | 26-07-10 | |
Nevan Elam
CEO | Chief Executive Officer | 56 | 26-07-10 |
Daron Evans
DFI | Director of Finance/CFO | 50 | 24/01 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Nevan Elam
CEO | Chief Executive Officer | 56 | 26-07-10 |
Young-Jin Kim
BRD | Director/Board Member | 67 | 10-02-19 |
Gil Labrucherie
BRD | Director/Board Member | 52 | 20-11-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,92% | 114 mld. | |
+10,48% | 104 mld. | |
-1,83% | 22,57 mld. | |
-6,45% | 22,5 mld. | |
-10,39% | 17,95 mld. | |
-42,36% | 16,48 mld. | |
-14,45% | 15,82 mld. | |
+3,76% | 13,55 mld. | |
+28,94% | 10,99 mld. |